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Abstract
Background:  The cervical mucus plug (CMP) is a semi-solid structure with antibacterial
properties positioned in the cervical canal during pregnancy. The CMP contains high concentrations
of matrix metalloproteinase 8 and 9 (MMP-8, MMP-9) and tissue inhibitor of metalloproteinase 1
(TIMP-1). This indicates a potential to degrade extracellular matrix components depending on the
balance between free non-complexed inhibitors and active enzymes.
Methods: Thirty-two CMPs collected during active labor at term were analyzed. Twelve CMPs
were separated into a cellular and an extracellular/fluid phase and analyzed by gelatin and reverse
zymography to reveal MMP and TIMP location. Twenty samples were homogenized, extracted and
studied by the TIMP activity assay based on gelatin zymography. Enzyme-linked immunosorbent
assay (ELISA) was used to determine TIMP-1, MMP-8 and MMP-9 protein concentrations, and
gelatin and reverse zymography used to identify gelatinases and TIMPs, respectively. The Western
blotting technique was applied for semi-quantification of alpha2-macroglobulin. An ELISA activity
assay was used to detect MMP-8 and MMP-9 activity.
Results: ProMMP-2, proMMP-9, TIMP-1 and TIMP-2 were almost exclusively located in the fluid
phase compared to the cellular phase of the CMP. All the extracted samples contained MMP-8,
MMP-9, TIMP-1, TIMP-2 and alpha2-macroglobulin. Free non-complexed TIMP was detected in all
the samples analyzed by the TIMP activity assay and was associated with TIMP-1 protein (R = 0.71,
p < 0.001) and with the TIMP/MMP molar ratio (1.7 (1.1–2.5) (mean (95% confidence interval)) (R
= 0.65, p = 0.002). The ELISA activity assay showed no activity from MMP-8 or MMP-9.
Conclusion: Due to their extracellular location, potential proteolytic activity from neutrophil-
derived MMPs in the CMP could exert a biological impact on cervical dilatation and fetal membrane
rupture at term. The functional TIMP activity assay, revealing excess non-complexed TIMP, and a
molar inhibitor/enzyme ratio above unity, indicate that refined MMP control prevents CMP-
originated proteolytic activity in the surrounding tissue.
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Background
The cervical mucus plug (CMP) constitutes a strong bar-
rier between the sterile uterine environment and the
microbe-rich vagina and protects the fetus from ascending
infection throughout pregnancy [1-3]. We now know that
the CMP not only has antibacterial properties, but also
contains high concentrations of the matrix metalloprotei-
nases (MMPs) gelatinase A (MMP-2), gelatinase B (MMP-
9) and neutrophil collagenase (MMP-8) together with
their specific inhibitors, the tissue inhibitors of metallo-
proteinases, TIMP-1 and TIMP-2 [4].
There exists an extensive quantity of literature on the sub-
ject of MMP and TIMP in human reproduction. We and
others have linked MMP protein in the CMP [4], the cervix
[5], the fetal membranes [6,7] and in amniotic fluid [8,9]
to proteolytic activity in connection with term and pre-
term birth. It is tempting to explain cervical dilatation and
membrane rupture solely on the basis of MMP protein
detection and presumed MMP activity. But the functional
balance between matrix-degrading enzymes and their
inhibitors [10,11] in the CMP and the heterogeneity of
cervical matrix biology [12,13], are fundamental to our
understanding of complicated multi-faceted processes
like term and preterm birth.
While working with MMP and TIMP in the cervical mucus
plug, an important question arises: does the detection of
MMP protein imply proteolytic activity? To answer this
question, we have conducted the present study where bio-
logical enzyme availability, i.e. enzyme and inhibitor
location in the CMP cellular or extracellular phases, will
be analyzed and discussed. Furthermore we will describe
the presence of free non-complexed MMP-inhibitors as an
indicator of the functional inhibitor-enzyme balance
using a TIMP activity assay.
Several traditional methods, such as enzyme-linked
immunosorbent assay (ELISA), reverse zymography and
western blotting, can detect TIMP protein [14]. Common
to all these methods is that they, together with the free
TIMP fraction, identify TIMP already complexed with
MMPs. Determination of the fraction of non-complexed
TIMP describes the physiological impact of MMP presence
and for this purpose we have developed the TIMP activity
assay which is able to estimate free TIMP.
The aim of the present work was to elucidate the proteo-
lytic capacity of the MMPs previously detected in the
CMP. This capacity depends upon three factors: whether
or not the enzymes are released from the cells, their acti-
vation status and finally the degree of inhibition by
endogenous inhibitors present in the fluid phase. The aim
was approached by 1) localization of MMP and TIMP pro-
teins to cell phase or fluid phase, 2) determination of the
molar ratio of MMP inhibitors/MMPs, 3) quantification
of active MMPs and 4) determination of non-complexed
TIMP by development of a TIMP activity assay.
Methods
Materials
The 32 intact CMPs included in this study were shed spon-
taneously or manually retrieved during vaginal explora-
tion (active labor, cervical dilatation from 2–10 cm). The
CMPs were either directly suspended in PBS (1:100) for
determination of TIMP and MMP distribution between
the cellular and the extracellular phases (n = 12, suspen-
sion group) or frozen for later extraction (n = 20, extrac-
tion group). The women were healthy and their mean age
was 29 (range 16–36) years; they had all been through a
normal pregnancy and delivered vaginally at term (gesta-
tional week 37–42). The Central Denmark Region Com-
mittee on Biomedical Research Ethics approved the
project and informed consent was obtained from each
patient. MMP-1EA (MMP-1 with no enzymatic activity
but retained TIMP-binding capacity) and APMA-activated
MMP-2 were kindly donated by Dr. Yoshifumi Itoh, The
Kennedy Institute of Rheumatology, Imperial College,
London.
CMP suspension
The samples (n = 12) were diluted directly after collection
without prior freezing. They were dissolved in PBS to a
final 1:100 dilution using a mantoux syringe to ensure
gentle suspension with no cell damage. After centrifuga-
tion (10 min, 500 g, 4°C), the supernatant (fluid phase)
and the precipitate (cell phase) were separated and the cell
phase was re-suspended to the original 1:100 dilution.
Cells were trypanblue dyed (0.5% w/w, Bie & Berntsen A/
S, Rødovre, DK) and counted (Bürker-Türk cell counter
chamber). To ensure that the suspension procedure did
not cause cell damage and protein leakage, it was per-
formed on two buffy coats containing fresh donor blood
leukocyte fractions supplied by the blood bank. Samples
were kept at -80°C until analysis.
CMP extraction
Samples (n = 20) were extracted as previously described
[4]. Briefly, mixed pulverized CMP was extracted in 50
mM Tris-HCl, 10 mM CaCl2, 0.05% Brij 35 and 1 mM
PMSF, pH 7.4 two times overnight at 4°C and once at
60°C (4 min). The three supernatants were pooled (final
1:100 dilution) and kept at -80°C until analysis.
Gelatin zymography
Gelatin zymography was performed on CMP extractions,
CMP suspensions and the two buffy coats. For the CMP
suspensions and the buffy coats, the purpose was to ana-
lyze gelatinase activity in the fluid and the cell phases.
From the identical fluid phase and cell phase dilutionsReproductive Biology and Endocrinology 2008, 6:45 http://www.rbej.com/content/6/1/45
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(1:100), 0.5 μl was loaded on a 10% gel. After electro-
phoresis performed as previously described [4], the
proMMP-2 and proMMP-9 bands were scanned using a
Shimadzu Cromato Scanner (CS-930, Shimadzu Corpora-
tion, Kyoto, Japan) for semi-quantification of gelatino-
lytic activity in the two phases.
Reverse zymography
Sixteen μl of fluid and cell phase (CMP and buffy coat sus-
pensions) or CMP extracts was mixed 1:1 with electro-
phoresis sample buffer and incubated for 15 min at 37°C,
and the gels (13%) were loaded with 30 μl of this mixture.
TIMPs were identified by comparison with the following
standards: TIMP-1 (4.0 ng/lane, Biogenesis, Pole, UK) and
TIMP-2 (4.0 ng/lane, Sigma-Aldrich).
TIMP activity assay
This assay is built on the premise that active, but not
inhibited, MMP-2 is entrapped by α2-macroglobulin
(α2M) [15]. By mixing CMP extract, APMA-activated
MMP-2, and α2M prior to gelatin zymography, it is possi-
ble to conclude on the presence of free inhibitor in the
sample since the MMP-2 (64 kDa) lysis band intensity is
brought to reflect the concentration of free inhibitor in the
CMP extracts. Figure 1 illustrates the basic principle of the
assay.
The CMP extracts (n = 20) were all scanned for the pres-
ence of free MMP inhibitors by α2M MMP-2 entrapment.
For each CMP, the wells were loaded with sample mixture
corresponding to sample A) CMP (2 μl) + MMP-2 (10 pg),
and sample B) CMP (2 μl) + MMP-2 (10 pg) + α2M (0.5
μg). Sample A versus sample B demonstrate the change in
MMP-2 (64 kDa) lysis activity when α2M is added to a
mixture of CMP and active MMP-2. Sample B) was pre-
pared by simultaneous mixing of MMP-2 and α2M (a gift
from Lars Sottrup-Jensen, Department of Molecular Biol-
ogy, University of Aarhus, Denmark) into the CMP
extract. This mixture was incubated for 30 min at 37°C.
Before electrophoresis on gelatin mini-gels (7.5%) per-
formed as previously described [4], all samples were
diluted 1:1 with electrophoresis sample buffer (4% SDS,
20% glycerol, 0.1% bromophenol blue, 125 mM Tris-
HCl, pH 6.8) and incubated for 15 min at 37°C. After
electrophoresis and staining, the MMP-2 (64 kDa) lysis
bands (representing the fraction of 10 pg MMP-2 that the
inhibitors in CMP were able to bind) were scanned and
the lysis intensity was quantified and compared to the
intensity of the standard containing 10 pg of active MMP-
2 alone.
Eight extracts were titrated at declining volumes (from 2.0
μl to 0.0625 μl) with constant MMP-2 (25 pg) and α2M
(0.5 μg) concentrations. Moreover, to test whether the free
inhibitor was indeed TIMP, other aliquots of these 8 sam-
ples (4 μl) were pre-incubated 15 min at room tempera-
ture with MMP-1EA (see Materials above) in excess (4 ng)
in order to capture all free TIMP possibly present in the
CMPs. Then, MMP-2 (20 pg) and α2M (1 μg) were added
simultaneously (total volume 10 μl). Half of the sample
volume (mixed 1:1 with sample buffer) was loaded onto
the gels and electrophoresed as described above. In this
test experiment, all the free TIMP present in the CMP sam-
ple is captured by MMP-1EA and MMP-2 is not expected
to give lysis band at 64 kDa (i.e. all MMP-2 is entrapped
by α2M) unless the CMP also contains non-TIMP inhibi-
tors. Control experiments to test the functionality of the
reagents comprised four wells: 1) α2M (0.5 μg), 2) MMP-
2 (10 or 25 pg), 3) MMP-2 + α2M, and, finally, 4) MMP-
2, TIMP-1 or TIMP-2 (50 pg) and α2M in combination.
Enzyme-linked immunosorbent assay (ELISA)
TIMP-1, MMP-8 and MMP-9 concentrations in the CMP
extracts were determined in duplicate by means of a com-
mercially available ELISA-kits based on a two-site sand-
wich format (GE Healthcare, Buckinghamshire, UK,
product number RPN2611, RPN2619 and RPN2614,
respectively). We have previously validated this assay sys-
tem for use on CMP extracts [4].
ELISA activity assay (GE Healthcare) was performed on
CMP extracts according to the manufacturer's instruc-
tions. Active MMP-8 (product number RPN2635) was
measured in a range between 0.75–24.0 ng/ml. The sensi-
tivity was 1.2 ng/ml, the inter-assay coefficient of varia-
tion (CV) was less than 19.0% and the intra-assay CV less
than 13.2%. Active MMP-9 (product number RPN2634)
was measured in a range between 0.5–16.0 ng/ml. The
sensitivity was 0.125 ng/ml, the inter-assay CV was less
than 43% and intra-assay CV was less than 21.7%.
Western blotting
Sixteen μl of CMP extracts was mixed 1:1 with electro-
phoresis sample buffer and incubated for 15 min at 37°C.
A 6% gel was loaded with 30 μl of sample mixture
together with α2M standard (10 ng and 50 ng). Following
electrophoresis under non-reducing conditions, proteins
were blotted to a PVDF membrane using a wet transfer
system (Bio-Rad Laboratories, California, USA) with cool-
ing in 25 mM Tris, 192 mM glycine, 0.05% SDS, pH 8.3 as
transfer buffer. Membranes were blocked with 0.5%
Tween 20/PBS for 0.5 h and then probed overnight at
37°C with primary antibody (rabbit anti-human α2M
(A033, DAKO, Glostrup, DK) diluted 1:500 in 0.5% skim
milk powder/0.05% Tween 20/PBS). For detection, we
used alkaline phosphatase-conjugated goat anti-rabbit
antibody (D487, DAKO) as secondary antibody and 5-
bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazo-
lium as substrate. The α2M content was semi-quantitatedReproductive Biology and Endocrinology 2008, 6:45 http://www.rbej.com/content/6/1/45
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Figure 1 (see legend on next page)
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in duplicate according to the standards using ImageJ soft-
ware (NIH, USA).
Statistics
To obtain a normal distribution and an equal variance,
the data were log-transformed when required. Linear
regression analysis was used to investigate the relation-
ship between the result of the TIMP activity assay and 1)
molar TIMP-1 concentration, 2) the molar inhibitor/
enzyme ratios as well as the relationship between concen-
trations of MMP-8 and MMP-9. Protein concentration and
molar ratio are presented as mean or geometric mean
(95% confidence interval (CI)). The Linear regression
analysis was performed and the confidence intervals cal-
culated using SigmaStat® 3.5 (Systat). P-values below 0.05
were considered significant.
Results
CMPs from 32 women in active vaginal delivery were ana-
lyzed. The mean weight was 5.15 g (range 0.94–11.7 g).
Twelve samples were directly diluted and separated into a
fluid and a cell phase for determination of TIMP and
MMP presence in the two phases. The remaining 20 sam-
ples were homogenized to obtain a representative meas-
ure of total MMP, TIMP and α2M protein.
TIMP and MMP location
We used reverse zymography and gelatin zymography to
determine the presence of TIMP and MMP in the CMP
fluid or cellular phases. ProMMP-2, proMMP-9, TIMP-1
and TIMP-2 were preferably located in the fluid phase
(Figure 2A and 2B). On the gelatin zymograms, the ratio
of proMMP-2 + proMMP-9 between the fluid phase and
the cell phase was estimated by scanning of lysis band
intensities and found to be 2.6 (1.4–3.8) (mean (95%
CI)). Control experiments with two buffy coats showed
MMP and TIMP to be located in the cell phases, which
confirmed that the suspension procedure did not damage
the cells with consequential MMP release (Figure 2C and
2D). All the 12 suspended plugs contained numerous
cells (8.05 × 103 (3.52 × 103-18.4 × 103) cells/mg CMP)
(geometric mean (95% CI)). The vast majority was recog-
nized as leukocytes, but epithelial cells and possibly mac-
rophages were also present. Five samples contained a few
vital cells, maybe due to fresh blood contamination; oth-
erwise all the cells were non-vital.
Inhibitor-enzyme balance
In Figure 3A the appearance and the functionality of the
reagents used in the TIMP activity assay are demonstrated.
This assay revealed free inhibitor in all 20 samples as illus-
trated by varying intensity of MMP-2 (64 kDa) lysis activ-
ity after α2M incubation (Figure 3B). After running a gel
with 8 samples premixed with constant concentrations of
active MMP-2 and α2M but with declining CMP extract
concentrations, the MMP-2 (64 kDa) lysis bands were
scanned. Lysis activity declined gradually with declining
CMP concentrations, which demonstrated the inhibitory
potential of each of the CMPs (Figure 3C). Capture of free
TIMP by excess amount of MMP-1EA (Figure 3D) revealed
that TIMP was not exclusively responsible for the inhibi-
tor activity: the MMP-2 (64 kDa) lysis band was not com-
pletely abolished (Figure 3D, lane 9) and, therefore, not
all the free inhibitor had been captured by MMP-1EA.
Nineteen samples contained TIMP-1 concentrations
detectable by ELISA (mean 4.71 (3.10–7.16) (95% CI)
ng/mg CMP) (molar concentration (fmol/mg CMP)
shown in Figure 4). The TIMP-1 concentration varied con-
siderably between the plugs (range < 1.25–29.0 ng/mg
CMP). A high TIMP-1 molar concentration was associated
with a large free inhibitor capacity as detected by the TIMP
activity assay (R = 0.71, p < 0.001) (Figure 5A). The molar
TIMP-1/(MMP-8 + MMP-9) ratio was above unity in 14 of
20 samples (mean 1.7 (1.1–2.7) (95% CI)) and associated
with free inhibitor capacity (R = 0.65, p = 0.002) (Figure
5B). All 20 plugs revealed bands from both TIMP-1 (28.5
kDa) and TIMP-2 (21.5 kDa) on the reverse zymograms
Schematic illustration of the TIMP activity assay Figure 1 (see previous page)
Schematic illustration of the TIMP activity assay. The steps involved in TIMP activity assay during incubation, SDS treat-
ment (inactivates MMPs, their reactivation is accomplished by SDS removal after electrophoresis) and zymography, respec-
tively. (A): Symbol explanation and schematic illustration, (B): schematic zymogram and (C): a true zymogram. In lane 1, α2M, 
represented in a monomeric form (180 kDa), is visible as a high molecular weight protein band at the gel top. In lane 2, activity 
from active MMP-2 is visible as a lysis band at 64 kDa. Lane 3 illustrates the basic principle of the assay: active MMP-2 cleaves 
the α2M bait region during incubation, is entrapped and stays covalently entrapped after SDS treatment. This is evident by a 
lysis band at the top of the zymogram together with α2M. In lane 4, MMP-2 is pre-incubated with TIMP before the adding of 
α2M. During this pre-incubation TIMP will bind to MMP-2 and inhibit enzyme activity. When α2M is thereafter added, MMP-2 
cannot cleave the bait region. The following SDS treatment disassociates TIMP from MMP-2, and MMP-2 reappears on the 
zymogram as a 64 kDa lysis band. In lane 5, TIMP-1 is pre-incubated with MMP-1EA (TIMP-binding capacity but without enzy-
matic activity) which results in TIMP-1 capture. When MMP-2 and α2M are thereafter simultaneously added, MMP-2 is active 
and free to cleave the α2M bait region resulting in entrapment. SDS disassociates the TIMP/MMP-1EA complex but the α2M-
MMP-2 complex stays intact. On the zymogram only the α2M-MMP-2 complex is visible at the gel top.Reproductive Biology and Endocrinology 2008, 6:45 http://www.rbej.com/content/6/1/45
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corresponding to the standards (not shown). Western blot
proved α2M presence in all the samples (Figure 6) and the
concentrations were semi-quantitatively estimated from
band intensity (mean 34.5 (20.0–59.4) (95% CI) ng/mg
CMP) (molar concentration (fmol/mg CMP) shown in
Figure 4). The molar ratio of total inhibitor (TIMP-1 +
α2M)/(MMP-8 + MMP-9) was above unity in 18 of 20
samples (mean 2.5 (1.7–3.7) (95% CI)) and associated
with free inhibitor capacity (R = 0.64, p = 0.002) (Figure
5C).
ELISA activity assays showed no active MMP-8 or active
MMP-9. The mean protein concentration was for MMP-8
3.98 (2.84–5.59) (95% CI) ng/mg CMP and for MMP-9
MMP and TIMP location Figure 2
MMP and TIMP location. (A): gelatin zymography (10% gel) and (B): reverse zymography (13% gel) on the same two CMP 
suspensions; lanes 1 and 3: CMP fluid phases; lanes 2 and 4: CMP cell phases. Both enzymes and inhibitors are almost exclu-
sively present in the fluid phases. (C): gelatin zymography performed on the two buffy coats; lanes 1 and 4: fluid phase, lanes 2–
3 and 5–6: duplex of cellular phase. (D): Reverse zymography. Lane 1: TIMP-1 standard (4 ng, 28.5 kDa), lane 2: TIMP-2 stand-
ard (4 ng, 21 kDa), lanes 3 and 5: fluid phase. Lanes 4 and 6: cellular phase. For the buffy coats, TIMPs and MMPs are present in 
the cellular phase.
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Figure 3 (see legend on next page)
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3.51 (2.65–4.65) (95% CI) ng/mg CMP (molar concen-
tration (fmol/mg CMP) shown in Figure 4). Total MMP-8
protein was directly proportional to total MMP-9 protein
(R = 0.85, P < 0.001) (not shown). Gelatin zymography
revealed the characteristic lysis bands from MMP-9: bands
at 184 kDa (dimer), at 125 kDa (MMP-9/NGAL complex),
and at 92 kDa (proMMP-9) in all 32 samples (not
shown). Moreover, 16 of 32 samples revealed proMMP-2
lysis bands at 72 kDa, but there were no signs of active
MMP-2 in any of the samples.
Discussion
With a combination of different methods we have tried to
assess the proteolytic capacity of the MMPs previously
Functional balance as illustrated by the TIMP activity assay Figure 3 (see previous page)
Functional balance as illustrated by the TIMP activity assay. Panel (A) shows the standards as follows: lane 1: α2M (0.5 
μg); lane 2: active MMP-2 (25 pg); lane 3: α2M + MMP-2; lane 4: MMP-2 + TIMP-2 + α2M. (B): TIMP activity assay applied to four 
different CMPs: lane 1: MMP-2 standard (10 pg), lane 2: MMP-2 + α2M. Lanes 3, 5, 7 and 9: CMP (2 μl) + MMP-2 (10 pg). Lanes 
4, 6, 8 and 10: CMP + MMP-2 + α2M. MMP-2 (64 kDa) lysis bands suggest that an inhibitor in the sample prevented α2M-MMP-
2 capture. (C): Titration of one inhibitor-positive plug. Lane 1–4: controls. Lanes 5–10: MMP-2 (64 kDa) lysis activity declines 
gradually with declining CMP concentration (2, 1, 0.5, 0.25, 0.125 and 0.0625 μl). (D): MMP-1EA-TIMP capture experiment. 
Lane 1–4: controls. Lane 5, MMP-1EA capture control: initial incubation of MMP-1EA (2 ng) and TIMP-1 (50 pg) followed by 
simultaneous addition of MMP-2 (10 pg) and a 2 M (0.5 μg); MMP-1EA forms a complex with TIMP-1 and allows α2M-MMP-2 
capture resulting in disappearance of MMP-2 (64 kDa) lysis band. In lane 6–9, the MMP-1EA-TIMP capture experiment is 
applied to a CMP. Lane 6: CMP (2 μl); lane 7: CMP + MMP-2 (10 pg); lane 8: CMP + MMP-2 + α2M (0.5 μg); lane 9: initially CMP 
and MMP-1EA (2 ng) followed by MMP-2 and α2M. MMP-2 (64 kDa), proMMP-2 (72 kDa), proMMP-9 (92 kDa), MMP-9-NGAL 
complex (125 kDa), MMP-9 dimer (184 kDa) and the α2M-MMP-2 complexes are indicated. The analysis was performed on a 
7.5% gel.
CMP content of enzymes and inhibitors Figure 4
CMP content of enzymes and inhibitors. The molar concentrations of CMP MMPs and inhibitors in fmol/mg CMP. Every 
dot represents a CMP (n = 20) and geometric mean values are indicated. Note the log-scale.
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Regression analysis Figure 5
Regression analysis. Linear regression analysis of TIMP activity assay results versus (A) TIMP-1 molar protein concentration 
(R = 0.71, p < 0.001), (B) the TIMP-1/(MMP-8 + MMP-9) molar ratio (R = 0.65, p = 0.002) and (C) the (TIMP-1 + α2M)/(MMP-
8 + MMP-9) molar ratio (R = 0.64, p = 0.002). The MMP-2 (64 kDa) lysis band intensities represent the fraction of 10 pg MMP-
2 that the inhibitors in CMP were able to bind in percent of the intensity of the standard containing 10 pg of active MMP-2 
alone.
	


	 	 	
















	










	
	
TIMP-1/(MMP-8 + MMP-9)
0.1 1 10 100
%
 
i
n
t
e
n
s
i
t
y
 
o
f
 
1
0
 
p
g
 
M
M
P
-
2
10
100
(TIMP-1 + D2M)/(MMP-8 + MMP-9)
0.1 1 10 100
%
 
i
n
t
e
n
s
i
t
y
 
o
f
 
1
0
 
p
g
 
M
M
P
-
2
10
100
A
B
CReproductive Biology and Endocrinology 2008, 6:45 http://www.rbej.com/content/6/1/45
Page 10 of 12
(page number not for citation purposes)
detected in the cervical mucus plug at term of pregnancy.
We mainly found both TIMP and MMP in the CMP fluid
phase which could mean that they play a role in the bio-
logical function of the CMP. If the CMP, when positioned
in the cervical canal during the course of pregnancy, can
be compared to CMPs collected during active labor at
term, the very high CMP MMP concentration might pro-
mote premature cervical softening and preterm premature
rupture of the membranes (PPROM). The risk of these
adverse effects is increased if the enzymes are both present
in the fluid phase and represented in their active forms.
Granulocyte counting in mucus from the external cervical
os reveals a significant increase in cells during the course
of pregnancy with a further increase during active labor
[16]. Microscopical observations performed on the mucus
plug show cell clusters mainly in the part of the plug fac-
ing the vagina, and the predominant cell type observed
here is the neutrophil leukocyte [3]. Therefore, the rela-
tively high concentrations of MMP-8 and MMP-9 found in
CMPs harvested during cervical dilatation probably
derives from neutrophil invasion of the CMP as also evi-
denced by the CMP neutrophil count performed in this
study. Indeed, the concentrations of MMP-8 and MMP-9
were correlated, which signifies a common cellular origin.
If the CMP MMP content primarily results from neu-
trophil leukocyte degranulation or apoptosis locally in the
plug, the enzyme concentration may simply reflect CMP
inflammation and antibacterial properties. The great
inter-individual variation in enzyme concentrations
among the CMPs analyzed could arise from differences in
vaginal flora virulence and the consequential CMP anti-
bacterial state of alert. MMP exudation from the dilating
cervix undergoing extensive remodeling [17-19] could
also contribute to CMP MMP, but to what degree is
unknown. Additionally, recruitment of neutrophils
caused by labor-induced inflammation may also add to
the MMP level that we detect. We suggest that the neu-
trophil-derived MMPs in the CMP are expressed through-
out pregnancy and reflect the main function of the CMP:
to prevent preterm birth by protecting the fetus from
ascending infection. As opposed to this clearly beneficial
impact of neutrophil presence, the MMP content of neu-
trophil secretory granules may affect the cervix as well as
the membranes in case of insufficient inhibition of the
activated enzymes.
The TIMP activity assay is a most interesting method that
builds on the basic principles of 1:1 stoichiometric MMP-
TIMP binding and α2M active proteinase entrapment,
thus detecting free MMP inhibitors. We have applied this
principle to the CMP and proved the functional inhibitor-
enzyme balance to be in favor of MMP-inhibition: all the
CMP extracts analyzed contained free MMP inhibitor in
various amounts. In spite of an extracellular location, the
CMP MMPs are likely to play a minor role in the extensive
cervical remodeling that occurs throughout an active birth
process.
No active MMP-8 or MMP-9 could be demonstrated by
the ELISA activity assays. The most abundant MMPs in the
CMP are not present in their active forms, but either in
their pro-forms or complexed with TIMPs. The possibility
exists that the concentrations of active MMPs are below
detection limit of the kits used since the physiological
concentrations of active MMPs in a tissue usually is very
low. However, due to excess free TIMP, as demonstrated
by the TIMP activity assay, this is not likely to be the case
when considering the CMP. Should the pro-forms
become activated, they will be immediately controlled by
the free TIMP fraction. The formation of complexes
between TIMPs and MMPs is rapid and strong; only
restricted momentary pericellular activity [20,21], and not
general proteolytic activity, is possible in a TIMP domi-
nated environment [22,23]. The potential activity of
MMP-8 and MMP-9 in the CMP seems to be tightly regu-
lated by MMP-inhibitors which prevent uncontrolled
CMP-originated proteolytic activity in the surrounding tis-
sues.
Efforts have been made to quantify the non-complexed
free fraction of TIMP-1 in plasma by means of an immu-
noassay technique [24]. Concerning the CMP, the TIMP
activity assay supplements immunodetection because it
creates an in vitro interaction between the endogenous free
α2-macroglobulin Western blot Figure 6
α2-macroglobulin Western blot. Lanes 1 and 2 contain 
standards, 10 and 50 ng α2M (180 kDa monomer), respec-
tively. Lanes 3–8 illustrate α2M in 6 different CMP extracts.
1           2            3            4             5            6           7           8
CMP D2M
10 ng
D2M
50 ng
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CMP inhibitor and the added, active MMP-2. A functional
reconstruction of highly complex interactions may allow
generalization of the results to actual in vivo conditions.
Control experiments with MMP-1EA capture of CMP
TIMP-1 showed that the free inhibitor was not represented
by TIMP-1 alone, but the association between the TIMP
activity assay results and a high TIMP/MMP molar ratio is
in favor of TIMP-1 being mainly responsible. A parallel
analysis using both techniques would clarify the issue of
non-complexed MMP inhibitor in the CMP and reveal if
the free inhibitor found here is actually TIMP-1.
On the basis of a molar ratio, we found 1.7 times as much
TIMP-1 in the CMP than MMP-8 and MMP-9 together
which support the inhibitor superiority detected by the
TIMP activity assay. When calculating the molar ratio, it
must be taken into consideration that only TIMP-1, MMP-
8 and MMP-9 were measured. According to our previous
studies [4], MMP-8 and MMP-9 are the two most abun-
dant MMPs present in the CMP. We have measured MMP-
1 and MMP-7 in CMP extracts and found them to be
undetectable. Neither MMP-3 could be detected (casein
zymography, unpublished data). MMP-2, on the other
hand, is measurable in low concentrations in extracted
CMP, but was not included in the present study. However,
other MMPs and MT-MMPs not yet characterized in the
CMP may also be potential inhibitor targets. The reverse
zymography showed TIMP-2 in the CMP samples, but
nevertheless the TIMP-2 concentration is unquantifiable
with the ELISA technique (levels below kit sensitivity (3.0
ng/ml)). Thus, the molar inhibitor-enzyme ratio calcu-
lated on the basis of our results should be taken merely as
an indication of an overall tendency towards inhibitor
superiority.
The TIMP source may be cervical tissue exudation,
endocervical gland secretion or secretion from vital or
dead cells already present in the plug. The CMP contains
predominantly neutrophil leukocytes but diverging opin-
ions exist regarding their ability to produce TIMP-1.
Opdenakke et al. state, that neutrophils are first-line
defense leukocytes and that they do not produce gelati-
nase A (MMP-2) or TIMP-1 [25]. On the other hand,
Triebel et al. have succeeded in isolating TIMP-1 from
neutrophils, which presumably allow these cells to con-
trol their own MMP activity [26]. Concerning the CMP,
the most likely option is that TIMP-1 is secreted from the
endocervical glands together with the mucus that consti-
tutes the plug.
If CMP TIMP originates from endocervical glands, the reg-
ulation of cervical TIMP synthesis and secretion must
adjust to the highly individual MMP content to reach the
refined enzymatic control that we describe. Such a regula-
tory mechanism is interesting in the context of preterm
birth; if the cervix fails to modify TIMP levels to CMP
MMP levels during the course of pregnancy, active prote-
olytic enzymes may cause cervical softening and/or
PPROM leading to preterm delivery. Much effort has been
displayed to use different inflammatory markers in cervi-
cal secretions to predict preterm labor [27]. A CMP sample
is easy to obtain, and with TIMP and MMP preferably
located in the fluid phase, these components can be relia-
bly quantified. Future analysis of TIMP and MMP in CMP
samples collected during the course of pregnancy may add
to our understanding of term labor mechanisms and pre-
term labor pathophysiology.
Conclusion
In the present study we found that MMP and TIMP are
located in the fluid rather than in the cellular phase of the
CMP at term, that the CMP displays molar inhibitor
excess, that the CMP contains no active MMP-8 or MMP-
9 and finally, that the CMP contains free non-complexed
MMP inhibitor which signifies a functional inhibitor
superiority.
Our results suggest that the CMP, with neutrophil-derived
MMPs available in the fluid phase, has a potential to dis-
play matrix degrading properties and therefore could play
a role in the cervical dilatation and fetal membrane rup-
ture at term. However, the TIMP activity assay, revealing
free non-complexed TIMP, and the detection of a molar
inhibitor/enzyme ratio above unity, indicate, that inhibi-
tor control hinders CMP-originated proteolytic activity in
the surrounding tissue. The regulation and biological
importance of the refined CMP inhibitor-enzyme balance
described here is yet to be established.
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